# Hemophilia Factors

This is a subcategory of Blood Formation, Coagulation, and Thrombosis Agents.


## Formulary

### Preferred

| Preferred       | Generic Name | Quantity | Time (Days) |
| :-------------- | :----------- | :------: | :---------: |
| Advate <sup>PA</sup>       |              |          |             |
| Adynovate <sup>PA</sup>    |              |          |             |
| Afstyla <sup>PA</sup>      |              |          |             |
| Alphanate <sup>PA</sup>   |              |          |             |
| Alphanine SD <sup>PA</sup> |              |          |             |
| Alprolix <sup>PA</sup>     |              |          |             |
| Benefix <sup>PA</sup>      |              |          |             |
| Corifact <sup>PA</sup>     |              |          |             |
| Eloctate <sup>PA</sup>     |              |          |             |
| Esperoct <sup>PA</sup>     |              |          |             |
| Feiba <sup>PA</sup>        |              |          |             |
| Hemlibra <sup>PA</sup>     |              |          |             |
| Hemofil M <sup>PA</sup>    |              |          |             |
| Humate-P <sup>PA</sup>     |              |          |             |
| Idelvion <sup>PA</sup>     |              |          |             |
| Ixinity <sup>PA</sup>      |              |          |             |
| Koate <sup>PA</sup>        |              |          |             |
| Kogenate FS <sup>PA</sup>  |              |          |             |
| Mononine <sup>PA</sup>    |              |          |             |
| Novoeight <sup>PA</sup>    |              |          |             |
| Novoseven RT <sup>PA</sup> |              |          |             |
| Profilnine <sup>PA</sup>   |              |          |             |
| Recombinate <sup>PA</sup> |              |          |             |
| Rixubis <sup>PA</sup>     |              |          |             |
| Wilate <sup>PA</sup>       |              |          |             |
| Xyntha <sup>PA</sup>      |              |          |             |

### Non-Preferred

| Non-Preferred | Generic Name | Quantity | Time (Days) |
| :------------ | :----------- | :------: | :---------: |
| Jivi          |              |          |             |
| Kovaltry      |              |          |             |
| Nuwiq         |              |          |             |
| Obizur        |              |          |             |
| Rebinyn       |              |          |             |
| Sevenfact     |              |          |             |
| Vonvendi      |              |          |             |

## Length of Authorizations

365 Days

## Grandfathering*

Patients who have a claim for a non-preferred drug in the previous 120 days will be automatically approved to continue the. Patients who have taken the drug previously but do not have claims history (e.g. new to Medicaid), will need to submit a prior authorization in order to continue coverage.

## All Authorizations

Must be prescribed in accordance with FDA approved labeling

## Clinical PA Criteria

- Must provide documentation of patient's body weight

## Non-Preferred Criteria

- Must provide documentation of medical necessity beyond convenience for why the patient cannot be changed to a preferred drug (i.e., allergies, drug-drug interactions, contraindications, or intolerances) **OR**
    - For any nonsolid oral dosage formulation: must provide documentation of medical necessity for why patient cannot be changed to a solid oral dosage formulation
- Must have had an inadequate clinical response of at least **14 days** with at least **one preferred** drug
    - For non-preferred extended-release formulations: must provide documentation of an inadequate clinical response with its immediate release formulation (if available)
    - For non-preferred brand names that have preferred generics: must provide documentation of an inadequate clinical response or allergy to two or more generic labelers (if available)

## Extended Half-Life Factor

Additional Extended Half-Life Factor Criteria

- Must provide attestation that the patient is not a suitable candidate for treatment with a shorter-acting half-life drug

## Subsequent Authorization Criteria

- Must provide documentation of patient's clinical response to treatment and ongoing safety monitoring

## Links

[Criteria](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL%20_Criteria_APPROVED.pdf#page=15)

[Preferred Drug List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_UPDL_APPROVED_12.13.22.pdf#page=9)

[Quantity Limit List](https://pharmacy.medicaid.ohio.gov/sites/default/files/20230101_Ohio_Medicaid_Quantity_Document_APPROVED.pdf)
